Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)

IR@PKUHSC > 北京大学临床肿瘤学院

学科主题	临床医学
	Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
	Van Cutsem, E.; Kang, Y.; Chung, H.; Shen, L.; Sawaki, A.; Lordick, F.; Hill, J.; Lehle, M.; Feyereislova, A.; Bang, Y.
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2009-06-20
卷	suppl.S 期:18
收录类别	SCI ; ISTP
文章类型	Meeting Abstract
WOS标题词	Science & Technology
类目[WOS]	Oncology
研究领域[WOS]	Oncology
语种	英语
WOS记录号	WOS:000276607000026
引用统计
文献类型	期刊论文
条目标识符	http://ir.bjmu.edu.cn/handle/400002259/55563
专题	北京大学临床肿瘤学院
作者单位	1.Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium 2.Asan Med Ctr, Seoul, South Korea 3.Yonsei Univ, Coll Med, Seoul, South Korea 4.Peking Univ, Sch Oncol, Beijing 100871, Peoples R China 5.Aichi Canc Ctr, Nagoya, Aichi 464, Japan 6.Natl Ctr Tumour Dis, Heidelberg, Germany 7.Roche Prod Pty Ltd, Dee Why, NSW, Australia 8.F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland 9.Seoul Natl Univ Hosp, Seoul 110744, South Korea
推荐引用方式 GB/T 7714	Van Cutsem, E.,Kang, Y.,Chung, H.,et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)[J]. JOURNAL OF CLINICAL ONCOLOGY,2009,suppl.S(18).
APA	Van Cutsem, E..,Kang, Y..,Chung, H..,Shen, L..,Sawaki, A..,...&Bang, Y..(2009).Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).JOURNAL OF CLINICAL ONCOLOGY,suppl.S(18).
MLA	Van Cutsem, E.,et al."Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)".JOURNAL OF CLINICAL ONCOLOGY suppl.S.18(2009).